Building a Renal Denervation Program-Introduction

Video Transcription

My name is Ty Cobayashi. I'm one of the interventionalists at the Huntsville University of Pennsylvania.  Erickson Samstian. I'm an interventional cardiologist at Beth Isgrove in Boston. Thank you so much for, on behalf of Sky and our industry partners, Petronic and ReCore,  thank you so much for showing up to this satellite session on renal generation. We're pretty excited about this.  It's going to be an interesting sort of session. It's going to be very unique in a couple of different ways.  One is that there's going to be a lot more non-interventional, non-cardiologists that are actually going to be joining our panel.  It's one of the first panels talking about the role of renal denervation, which is yet to be FDA approved, so an investigational device in the armamentarium of hypertension.  So we're going to be mostly focused on how to start to build your program so that you're ready for renal denervation  when it becomes available. And so you'll see that we're mostly focused on what we thought we would do,  is we bring together a panel of our highest level experts to kind of talk about their experience,  how to build a program, and move on from there. So I'll get started with the first session here.  Yeah, so again, I think we've kind of built up and filled some gaps that we haven't covered in other RDN sessions.  And so I think the last part of this is probably going to be one of the most important aspects of where we go from here.  And I made this comment earlier that hopefully this is the last time at SC&I that we have a conversation about this therapy without it being available clinically on the market.  And so I'm going to stand by that comment, and hopefully it will help all of us get there in the near future.  So to not belabor this, we're going to start our first session, which we called State of the Union.  And there's no better people to be part of this than Michael Bloch from Rhode Island Medical Center in Reno, as well as Debbie Cohen from the University of Pennsylvania.

Video Summary

In this video, Ty Cobayashi and Erickson Samstian, interventionalists at Huntsville University and Beth Isgrove respectively, thank industry partners Petronic and ReCore for attending a satellite session on renal generation. The panel discussion, one of the first on the role of renal denervation in hypertension treatment, focuses on building a program to prepare for the device's availability post-FDA approval. The session features high-level experts, including Michael Bloch and Debbie Cohen, who share their experiences and discuss the state of the therapy. They hope that this will be the last time discussing it without it being clinically available.

Asset Subtitle

Tai Kobayashi, MD, FSCAI

Keywords

renal denervation

hypertension treatment

FDA approval

high-level experts

clinical availability